Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 60Neoplasms 41Carcinoma, Non-Small-Cell Lung 32Ovarian Neoplasms 27Neoplasm Metastasis 22Glioblastoma 19Lung Neoplasms 17Fallopian Tube Neoplasms 16Colonic Neoplasms 16Breast Neoplasms 16Rectal Neoplasms 15Pancreatic Neoplasms 15Carcinoma, Renal Cell 13Carcinoma, Hepatocellular 12Stomach Neoplasms 10Glioma 10Carcinoma, Ovarian Epithelial 8Solid Cancers 7Sarcoma 7Melanoma 7Liver Neoplasms 7Brain Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumors 6Uterine Cervical Neoplasms 5Recurrence 5Lymphoma, Non-Hodgkin 5Astrocytoma 5Advanced Cancer 5Triple Negative Breast Neoplasms 4

Interventions

pembrolizumab 2fludarabine 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Microsatellite Instability × Bevacizumab × Clear all
NCT06004245 2026-05-08

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
280 enrolled
Gastrointestinal

Colorectal Neoplasms, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡